• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

CPhI South East Asia Set for Indonesia


January 13, 2017

Continuing to reflect the rapid development of the South East Asia (SEA) pharmaceutical markets and Indonesia in particular, CPhI SEA, the only trade exhibition dedicated to the pharma industry in the region, will be taking place this year at Indonesia’s Jakarta International Expo during March 22-24.   The SEA pharma markets have been developing at 6%–10% year on year and are expected to deliver further remarkable future growth. Indonesia is the largest market in the region with a population of 250m people, and represents almost 40% of the SEA's economic output and the largest pharma manufacturing base in the entire region.   Governments across SEA have been introducing universal healthcare programs. This is driving rising demand for all categories of medicines, especially generic drugs. Since launching its mandatory healthcare coverage program (JKN) in 2014, Indonesia's government healthcare spending has increased by 4%, and reached USD 7.8 billion in 2016.   Nevertheless, CPhI reports, success in the region will be fully achieved only if the strengths of the countries will be integrated and combined in a network of business partnerships, JVs, M&A that spur innovation, the development of high margin drugs, enhance markets penetration and ultimately create value over the board.   CPhI SEA will host a highly focused conference with additional features ranging from the South East Asian distributors' forum, the packaging forum, the innovation gallery and the investment forum.    View the full conference program here.

Related Videos